Patient Preferences for Attributes of Chemotherapy for Lung Cancer: Discrete Choice Experiment Study in Japan.
Japanese patient preferences
conjoint analysis
discrete choice experiment
hierarchical bayes model
lung cancer
patient centricity
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
04
2021
accepted:
06
07
2021
entrez:
6
8
2021
pubmed:
7
8
2021
medline:
7
8
2021
Statut:
epublish
Résumé
Our study objective was to determine lung cancer chemotherapy attributes that are important to patients in Japan. A discrete choice experiment survey in an anonymous web-based questionnaire format with a reward was completed by 200 lung cancer patients in Japan from November 25, 2019, to November 27, 2019. The relative importance of patient preferences for each attribute was estimated using a conditional logit model. A hierarchical Bayesian logit model was also used to estimate the impact of each demographic characteristic on the relative importance of each attribute. Of the 200 respondents, 191 with consistent responses were included in the analysis. In their preference, overall survival was the most important, followed by diarrhea, nausea, rash, bone marrow suppression (BMS), progression-free survival, fatigue, interstitial lung disease, frequency of administration, and duration of administration. The preferences were influenced by demographic characteristics (e.g., gender and age) and disease background (e.g., cancer type and stage). Interestingly, the experience of cancer drug therapies and adverse events had a substantial impact on the hypothetical drug preferences. For the Japanese lung cancer patients, improved survival was the most important attribute that influenced their preference for chemotherapy, followed by adverse events, including diarrhea, nausea, rash, and BMS. The preferences varied depending on the patient's demographic and experience. As drug attributes can affect patient preferences, pharmaceutical companies should be aware of the patient preferences and develop drugs that respond to segmented market needs.
Identifiants
pubmed: 34354590
doi: 10.3389/fphar.2021.697711
pii: 697711
pmc: PMC8329447
doi:
Types de publication
Journal Article
Langues
eng
Pagination
697711Informations de copyright
Copyright © 2021 Sugitani, Ito and Ono.
Déclaration de conflit d'intérêts
YS and KI are employees of the pharmaceutical industry, Chugai Pharmaceutical Co., Ltd. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lung Cancer. 2011 May;72(2):213-8
pubmed: 20817340
J Thorac Oncol. 2016 Mar;11(3):300-11
pubmed: 26723244
BMC Cancer. 2018 Jan 15;18(1):79
pubmed: 29334910
Future Oncol. 2019 Dec;15(34):3895-3907
pubmed: 31621403
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Patient. 2020 Oct;13(5):521-536
pubmed: 32686052
Am J Respir Crit Care Med. 2010 Mar 15;181(6):566-77
pubmed: 20019345
Clin Transl Oncol. 2020 Jun;22(6):935-942
pubmed: 31559581
JAMA Oncol. 2019 Dec 1;5(12):1779-1789
pubmed: 31556921
J Thorac Oncol. 2010 Oct;5(10):1668-72
pubmed: 20871267
Radiother Oncol. 2016 Nov;121(2):225-231
pubmed: 27717511
Lung Cancer. 2010 Aug;69(2):141-7
pubmed: 20570009
Patient Prefer Adherence. 2016 Sep 26;10:1945-1956
pubmed: 27713622
Value Health. 2016 Jun;19(4):300-15
pubmed: 27325321
Value Health. 2016 Sep - Oct;19(6):734-740
pubmed: 27712699
Intern Med. 2005 Feb;44(2):107-13
pubmed: 15750269
J Clin Oncol. 2015 Aug 10;33(23):2563-77
pubmed: 26101248
J Cancer Res Clin Oncol. 2016 Mar;142(3):699-706
pubmed: 26577827
Psychooncology. 2009 May;18(5):483-9
pubmed: 18942662
Lung Cancer. 2012 Jul;77(1):224-31
pubmed: 22369719
Psychosom Med. 2003 Nov-Dec;65(6):938-43
pubmed: 14645770
Value Health. 2011 Jun;14(4):403-13
pubmed: 21669364
Eur J Health Econ. 2015 Jul;16(6):657-70
pubmed: 25135768
Patient Prefer Adherence. 2017 Sep 26;11:1647-1656
pubmed: 29033552
Value Health. 2013 Jan-Feb;16(1):3-13
pubmed: 23337210
Clin Pharmacol Ther. 2011 Feb;89(2):312-5
pubmed: 21160469
Clin Transl Oncol. 2012 Mar;14(3):183-9
pubmed: 22374421
Health Econ. 2012 Feb;21(2):145-72
pubmed: 22223558
Eur J Cancer Care (Engl). 2016 Jul;25(4):580-91
pubmed: 26676876
Qual Life Res. 2006 Mar;15(2):285-98
pubmed: 16468083
Qual Life Res. 2009 Oct;18(8):1095-103
pubmed: 19626462
Oncologist. 2018 Jan;23(1):44-51
pubmed: 29079638
Drug Discov Today. 2019 Jan;24(1):57-68
pubmed: 30266656
Cancer Epidemiol Biomarkers Prev. 2020 May;29(5):942-948
pubmed: 32132149
Cancer. 2014 Dec 1;120(23):3651-9
pubmed: 25091693
Lancet. 2018 Mar 17;391(10125):1023-1075
pubmed: 29395269
Patient. 2019 Dec;12(6):553-557
pubmed: 31696436
Appl Health Econ Health Policy. 2003;2(1):55-64
pubmed: 14619274
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv192-iv237
pubmed: 30285222
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
J Clin Oncol. 2017 Oct 20;35(30):3484-3515
pubmed: 28806116
Patient Prefer Adherence. 2019 Oct 08;13:1701-1709
pubmed: 31631985
Curr Med Res Opin. 2017 Feb;33(2):261-268
pubmed: 27779433